To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of CoronaVac or BBIBP-CorV.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
480
the third dose immunization schedule of SARS-CoV-2 inactivated vaccine
Xiangyang City Centers for Disease Control and Prevention
Xiangyang, Hubei, China
RECRUITINGSeroconversion rate of Neutralizing and IgG antibodies against SARS-CoV-2
Seroconversion rate of neutralizing antibodies and IgG against SARS-CoV-2 in serum for the third dose immunization schedule
Time frame: From 0 days to 6 month after the third dose
SARS-CoV-2 specific memory B and T cell response
SARS-CoV-2 specific memory B and T cell response for the third dose immunization schedule
Time frame: From 0 days to 6 month after the third dose
Adverse reactions/events rate
Occurence of adverse reactions/events after vaccination
Time frame: 7 days after vaccination
Adverse reactions/events rate
Occurence of adverse reactions/events after vaccination
Time frame: 28 days after vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.